Sai Life Sciences Ltd carries out contract research and manufacturing activities for customers engaged in pharmaceutical and bio technology industriesBusiness Overview: a) SLS is a Hyderabad-based contract research development and manufacturing organisation in the pharmaceutical sector with a significant presence in regulatory markets of US and Europe. b) It offers...
Sai Life Sciences kicked off FY27 with a robust Q1, reporting revenue of ₹554 Cr, up 12% year-on-year. Its Contract Research Organization (CRO) segment drove significant momentum with 24% YoY growth, while the Contract Development and Manufacturing Organization (CDMO) pipeline strengthened with 33 active commercial molecules. Profit After Tax (PAT)...
Sai Life Sciences posted robust FY26 results with consolidated revenue climbing 29% to ₹2,192 Cr. Both CDMO (up 33% to ₹1,417 Cr) and CRO (up 24% to ₹775 Cr) segments showed strong growth. Profit After Tax (PAT) more than doubled, increasing 109% to ₹355 Cr, while EBITDA rose 56% to...
Sai Life Sciences delivered robust Q3 FY26 growth, outperforming the CRDMO industry. Revenue reached ₹556 Cr (+27% YoY), fueled by strong demand across CDMO (+31% YoY) and CRO (+19% YoY) services. EBITDA surged 54% YoY to ₹191 Cr, with margins expanding to 34%. Net profit jumped 86% YoY to ₹100...
Sai Life Sciences delivered a strong performance, with Q2FY26 revenue up 36% YoY to ₹537 Cr and H1FY26 revenue growing 53% YoY to ₹1,034 Cr. This growth was fueled by healthy demand across both CRO (Contract Research Organization) and CDMO (Contract Development and Manufacturing Organization) services. Profit after tax (PAT)...
1. **Financial Highlights:** Sai Life Sciences reported strong Q1FY26 results: revenue up 77% YoY to ₹496 Cr, led by 113% CDMO growth. EBITDA surged 305% YoY to ₹125 Cr (25% margin). PAT reached ₹60 Cr, with ₹134 Cr invested in capex. 2. **Strategic Initiatives & Growth Drivers:** Aggressive expansion for...
